Compare Crispr Therapeutics AG (CRSP) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PAGSEG Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and PAGSEG Inc pays a 10.49% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and PAGSEG Inc for 26 Days on average.
| CRSP | PAGS | |
|---|---|---|
Market Cap | $4.88B | $2.94B |
Volume | 2,861,747 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $74.92 | $12.00 |
52-Week Low | $44.34 | $8.44 |
Typical Hold Time | 77 Days | 26 Days |
Enterprise Value | $3.30B | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
PAGS trades at $10.68, up 1.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong fundamentals with a P/E of 7.1, net income margin of 10.45%, and a dividend yield supported by a recent $0.28 payout. Recent earnings beat expectations in Q2 2026, and cash flow from operations remains robust at $7.56 billion for 2025.
The outlook is positive given undervaluation metrics and institutional support, but risks include a projected negative net cash flow for 2026 and high RSI levels suggesting overbought conditions. Earnings growth and banking segment expansion are key catalysts, while macroeconomic pressures in Brazil present headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
